MedTrace Logo

Oxybutynin for Post-surgical Bladder Pain and Urgency

NCT03952299 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-29

No results posted yet for this study

Summary

Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.

Conditions

  • Overactive Bladder Syndrome
  • Neuropathic Bladder

Interventions

DRUG

Oxybutynin Transdermal Patch

Transdermal patch of oxybutynin will be used instead of oral oxybutynin.

DRUG

Oral Oxybutynin

Oral administration of oxybutynin (5mg) every 8 hours in the hospital.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Eric A Kurzrock, MD · UC Davis Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03952299 on ClinicalTrials.gov